IceCure Medical (NASDAQ:ICCM) Posts Earnings Results, Misses Expectations By $0.03 EPS

IceCure Medical (NASDAQ:ICCM) issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03), Zacks reports. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.The business had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million.

Here are the key takeaways from IceCure Medical’s conference call:

• IceCure reported Q1 2026 revenue growth of 26% year over year, with North America up 84% and U.S. sales up 31%, driven by a new system placement and higher disposable probe usage.
• The company said U.S. commercial momentum accelerated after FDA clearance for low-risk early breast cancer, with active accounts rising to 19 from 13 pre-clearance, and it expects further growth in the second quarter.
• Management described strong physician and hospital interest in ProSense at major conferences, saying qualified leads are moving through purchasing processes and could convert into system sales and installations over the coming quarters.
• IceCure is expanding its U.S. sales team and advancing the ChoICE post-market study, which will include 30 hybrid clinical/commercial sites and is intended to support adoption, generate additional data, and help reimbursement efforts.
• Reimbursement remains a work in progress: the company plans to submit the CPT 1 code application in June, expects a response in 2027, and believes it could become effective in January 2028, while also pursuing transitional pass-through payment.

IceCure Medical Trading Down 4.6%

IceCure Medical stock traded down $0.20 during mid-day trading on Monday, reaching $4.16. The company had a trading volume of 40,736 shares, compared to its average volume of 25,906. IceCure Medical has a fifty-two week low of $3.75 and a fifty-two week high of $42.00. The company has a market cap of $11.69 million, a P/E ratio of -0.58 and a beta of 0.40. The business has a fifty day simple moving average of $8.24 and a 200 day simple moving average of $15.44.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Jane Street Group LLC purchased a new stake in IceCure Medical Ltd. (NASDAQ:ICCM) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned approximately 0.16% of IceCure Medical as of its most recent SEC filing. Institutional investors own 0.62% of the company’s stock.

Wall Street Analysts Forecast Growth

ICCM has been the subject of several recent analyst reports. Alliance Global Partners started coverage on shares of IceCure Medical in a research note on Monday, May 4th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Finally, Maxim Group cut their price objective on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $62.70.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.